Adjuvant ganglioside GM2-KLH/QS-21 vaccination: post-operative adjuvant ganglioside GM2-KLH/QS-21 (BMS-248479) vaccination treatment after resection of primary cutaneous melanoma thicker than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial vs. observation.

Trial Profile

Adjuvant ganglioside GM2-KLH/QS-21 vaccination: post-operative adjuvant ganglioside GM2-KLH/QS-21 (BMS-248479) vaccination treatment after resection of primary cutaneous melanoma thicker than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-arm multicenter randomized phase III trial vs. observation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Melanoma vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results assessing IgG serum antibody responses of stage II melanoma patients of the EORTC 18961 trial presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 09 Dec 2015 Accrual till date is 32% according to United Kingdom Clinical Research Network record.
    • 09 Sep 2013 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top